CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Niacin +1 moredrug
Likely dose
Niacin 6000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02003638
NCT02003638N/ACompleted
CompareCT.gov

A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY FLUORODEOXYGLUCOSE-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES

University of Pennsylvania·interventional·Posted Dec 6, 2013·Updated Jun 25, 2014

In Brief

A clinical study evaluating Niacin and Placebo for Coronary Artery Disease and 2 related conditions. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic statin therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Carotid Artery Disease, Peripheral Artery Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 6, 2013
Enrollment StartMar 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.6 years ago

Interventions

Niacindrug

Niacin titrated to 6000 mg daily

Placebodrug

Placebo provided in the same pill quantity as niacin arm